{"id":"W4281385697","doi":"10.1182/blood.2021015014","title":"Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":151,"is_retracted":false,"has_abstract":true,"ca_institutions":"Jewish General Hospital; University of Calgary","funders":"National Cancer Institute; University of Texas MD Anderson Cancer Center; National Institutes of Health; Servier; BeiGene; Adaptive Biotechnologies; TG Therapeutics; Incyte; F. Hoffmann-La Roche; Amsterdam University Medical Centers; Gilead Sciences; Universiteit van Amsterdam; Leukemia and Lymphoma Society; GlaxoSmithKline; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; Amgen; Breast Cancer Research Foundation; Celgene; Pharmacyclics; Genentech; California Institute for Regenerative Medicine","keywords":"Rituximab; Medicine; Venetoclax; Bendamustine; Internal medicine; Regimen; Population; Progression-free survival; Oncology; Chemotherapy regimen; Gastroenterology; Chemotherapy; Surgery; Chronic lymphocytic leukemia; Leukemia; Lymphoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002546189,0.0002411047,0.0006783395,0.0004550753,0.0002257777,0.0006869396,0.0003514143,0.0004448398,0.0008768669],"category_scores_gemma":[0.003127485,0.0001120735,0.0007950591,0.0005059104,0.0002376724,0.0006825319,0.0004073826,0.0008647512,0.0001685733],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004761363,"about_ca_system_score_gemma":0.0002552711,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009863474,"about_ca_topic_score_gemma":0.001294597,"domain_scores_codex":[0.9992686,0.0002926311,0.00006453411,0.0001195612,0.0001252335,0.0001294089],"domain_scores_gemma":[0.9969667,0.0007045274,0.001563173,0.0002055381,0.0001759976,0.0003840982],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1000494,0.001368555,0.7408018,0.0004296196,0.001676747,0.000444631,0.000358014,0.003098695,0.003911972,0.0003241507,0.001558108,0.1459783],"study_design_scores_gemma":[0.001783888,0.01924475,0.9711154,0.0000842703,0.001402413,0.0008394849,0.00009604899,0.001373246,0.001392431,0.0004868383,0.002136688,0.00004449431],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9958229,0.002588726,0.0001732045,0.00007352855,0.00001313406,0.0000188762,0.0005140313,0.00001043812,0.0007851846],"genre_scores_gemma":[0.9982671,0.000327183,0.0001007162,0.00006088773,0.00002762907,0.00001792506,0.0009580821,0.000002736249,0.0002377431],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002546189,"threshold_uncertainty_score":0.0134657,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01165059563415755,"score_gpt":0.260368235767024,"score_spread":0.2487176401328665,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}